Form D · Pharmaceuticals
Bantam Pharmaceutical, LLC
New York, NY · CIK 0001650608
Offering snapshot reported Aug 11, 2015 · SEC filing
- Reported sold
- $7M Offering amount: $8M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $500K Reported outside-investor minimum
- First sale
- Jul 13, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 11, 2015 | Initial | $7,000,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-245501
Source: Form D, filed Aug 11, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lionel Goldfrank, Iii | Director, Promoter |
| Victor F. Keen | Director, Promoter |
| W. James Tozer, Jr. | Director, Promoter |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
424 West 33 Rd Street Suite 540
New York, NY, 10001
New York, NY, 10001